Novel perspectives in celiac disease therapy

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 359-367

  Sanz, Yolanda ^a  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

Author keywords

Celiac disease; Gluten; Immunity; Intestinal microbiota; Permeability; Probiotics; Therapy

Indexed keywords

2 [(2 OXOPROPYL)THIO]IMIDAZOLIUM DERIVATIVE; ADALIMUMAB; AMG 714; AT 1001; CCX 282B; CERTOLIZUMAB PEGOL; CHEMOKINE RECEPTOR ANTAGONIST; CYCLOPEPTIDE; CYSTAMINE; DANSYLCADAVERINE; GAMMA INTERFERON ANTIBODY; GLUTAMINYLGLUTAMINYLPROLYLGLUTAMINYLASPARTYLALANYLVALYLGLUTAMINYLPROLYLPHENYLALANINE; HALODIHYDROXYISOXAZOLE; IMIDAZOLE DERIVATIVE; INFLIXIMAB; KCC 009; L 682777; LEUCYLGLUTAMINYLLEUCYLGLUTAMINYLPROLYLPHENYLALANYLGLUTAMINYLPROLYLGLUTAMYLLYSYLPROLYLTYROSYLPROLYLGLUTAMINYLPROLYLGLUTAMYLLYSYLPROLYLTYROSINE; LEUCYLGLUTAMINYLPROLYLPHENYLALANYLPROLYLGLUTAMINYLPROLYLGLUTAMYLLEUCYLPROLYTYROSINE; MLN 02; NATALIZUMAB; PEPTIDE DERIVATIVE; PROBIOTIC AGENT; PROLINE IMINOPEPTIDASE; PROLYL ENDOPEPTIDASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONULIN RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYTOKINE; ENZYME INHIBITOR; GLUTEN; IMMUNOSUPPRESSIVE AGENT; PEPTIDE HYDROLASE; ZONULA OCCLUDENS TOXIN RECEPTOR;

ADJUVANT THERAPY; BIFIDOBACTERIUM ANIMALIS; CELIAC DISEASE; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; ENTERITIS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GLUTEN FREE DIET; HUMAN; INTESTINE FLORA; LACTOCOCCUS LACTIS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM;

CELIAC DISEASE; CELL ADHESION MOLECULES; CYTOKINES; ENZYME INHIBITORS; GLUTENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEPTIDE HYDROLASES; PROBIOTICS; RECEPTORS, CELL SURFACE;

EID: 65349175633     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030359     Document Type: Review

References (63)

1. Green, P.H.; Jabri, B. Celiac disease. Annu. Rev. Med., 2006, 57, 207-21.
2. Fasano, A.; Catassi, C. Coeliac disease in children. Best Pract. Res. Clin. Gastroenterol., 2005, 19, 467-78.
3. Black, K.E.; Murray, J.A.; David, C.S. HLA-DQ determines the response to exogenous wheat proteins: a model of gluten sensitivity in transgenic knockout mice. J. Immunol., 2002, 169, 5595-600.
4. Kagnoff, M.F. Overview and pathogenesis of celiac disease. Gastroenterology, 2005, 128, S10-8.
5. Stenberg, P.; Roth, E.B.; Sjöberg, K. Transglutaminase and the pathogenesis of coeliac disease. Eur. J. Intern. Med., 2008, 19, 83-91.
6. Gianfrani, C.; Auricchio, S.; Troncone R. Adaptive and innate immune responses in celiac disease. Immunol. Lett., 2005, 99, 141-5.
7. Di Sabatino, A.; Ciccocioppo, R.; Cupelli, F.; Cinque, B.; Millimaggi,. D; Clarkson, M.M.; Paulli, M.; Cifone, M.G.; Corazza, G.R. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut, 2006, 55, 469-77.
8. Fasano, A.; Shea-Donohue, T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat. Clin. Pract. Gastroenterol. Hepatol., 2005, 2, 416-22.
9. Tjellström, B.; Stenhammar, L.; Högberg, L.; Fälth-Magnusson, K.; Magnusson, K.E.; Midtvedt, T.; Sundqvist, T.; Norin, E. Gut microflora associated characteristics in children with celiac disease. Am. J. Gastroenterol., 2005, 100, 2784-8.
10. Nadal, I.; Donat, E.; Ribes-Koninckx, C.; Calabuig, M.; Sanz, Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J. Med. Microbiol., 2007, 56, 1669-74.
11. Collado, M.C.; Calabuig, M.; Sanz, Y. Differences between the fecal microbiota of coeliac infants and healthy controls. Curr. Issues Intest. Microbiol., 2007, 8, 9-14.
12. Ivarsson, A.; Hernell, O.; Nystrom, L.; Persson, L.A. Children born in the summer have increased risk for coeliac disease. J. Epidemiol. Commun. Health, 2003, 57, 36-9.
13. Kondrashova, A.; Mustalahti, K.; Kaukinen, K.; Viskari, H.; Volodicheva, V.; Haapala, A.M.; Clonen, J.; Knip, M.; Mäki, M.; Hyöty, H. Epivir Study Group. Lower economic status and inferior hygienic environment may protect against celiac disease. Ann. Med., 2008, 40, 223-31.
14. Rewers, M. Epidemiology of coeliac disease: what are the prevalence, incidence, and progression of coeliac disease? Gastroenterology, 2005, 128, S47-51.
15. Shan, L.; Marti, T.; Sollid, L.M.; Gray, G.M.; Khosla, C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem. J., 2004, 383, 311.
16. Sanz, Y. In Industrial Enzymes: Structure, Function and Applications, Polaina, J.; McCabe, A., Eds. Springer: The Netherlands, 2007; pp 243-260.
17. Garcia-Horsman, J.A.; Venäläinen, J.I.; Lohi, O.; Auriola, I.S.; Korponay-Szabo, I.R.; Kaukinen, K.; Mäki, M.; Männistö, P.T. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scand. J. Gastroenterol., 2007, 42, 562-71.
18. Stepniak, D.; Spaenij-Dekking, L.; Mitea, C.; Moester, M.; de Ru, A.; Baak-Pablo, R.; van Veelen, P.; Edens, L.; Koning, F. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 291, G621-9.
19. Pyle, G.G.; Paaso, B.; Anderson, B.E.; Allen, D.D.; Marti, T.; Li, Q.; Siegel, M.; Khosla, C.; Gray, G.M. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin. Gastroenterol. Hepatol. 2005, 3, 687-94.
20. Mitea, C.; Havenaar, R.; Drijfhout, J.W.; Edens, L.; Dekking, L.; Koning, F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut, 2008, 57, 25-32.
21. Gass, J.; Bethune, M.T.; Siegel, M.; Spencer, A.; Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology, 2007, 133, 472-80.
22. Savijoki, K.; Ingmer, H.; Varmanen, P. Proteolytic systems of lactic acid bacteria. Appl. Microbiol. Biotechnol., 2006, 71, 394-406.
23. Di Cagno, R.; Rizzello, C.G.; De Angelis, M.; Cassone, A.; Giuliani, G.; Benedusi, A.; Limitone, A.; Surico, R.F.; Gobbetti, M. Use of selected sourdough strains of Lactobacillus for removing gluten and enhancing the nutritional properties of gluten-free bread. J. Food. Prot., 2008, 71, 1491-5.
24. Molberg, O.; Mcadam, S.N.; Körner, R.; Quarsten, H.; Kristiansen, C.; Madsen, L.; Fugger, L.; Scott, H.; Norén, O.; Roepstorff, P.; Lundin, K.E.; Sjöström, H.; Sollid, L.M. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gutderived T cells in celiac disease. Nat. Med., 1998, 4, 713-7.
25. Zanoni, G.; Navone, R.; Lunardi, C.; Tridente, G.; Bason, C.; Sivori, S.; Beri, R.; Dolcino, M.; Valletta, E.; Corrocher, R.; Puccetti, A. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med., 2006, 3, e358.
26. Myrsky, E.; Kaukinen, K.; Syrjänen, M.; Korponay-Szabó, I.R.; Mäki, M.; Lindfors, K. Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin. Exp. Immunol., 2008, 152, 111-9.
27. Siegel, M.; Xia, J.; Khosla, C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg. Med. Chem., 2007, 15, 6253-61.
28. Maiuri, L.; Ciacci, C.; Ricciardelli, I.; Vacca, L.; Raia, V.; Rispo, A.; Griffin, M.; Issekutz, T.; Quaratino, S.; Londei, M. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology, 2005, 129, 1400-13.
29. Choi, K.; Siegel, M.; Piper, J.L.; Yuan, L.; Cho, E.; Strnad, P.; Omary, B.; Rich, K.M.; Khosla, C. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol., 2005, 12, 469-75.
30. Telci, G.; Griffin, M. Tissue transglutaminase (TG2)-a wound response enzyme. Front. Biosci., 2006, 11, 867-82.
31. Xia, J.; Bergseng, E.; Fleckenstein, B.; Siegel, M.; Kim, C.Y.; Khosla, C.; Sollid, L.M. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg, Med, Chem., 2007, 15, 6565-73.
32. Silano, M.; Di Benedetto, R.; Trecca, A.; Arrabito, G.; Leonardi, F.; De Vincenzi, M. A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr. Res., 2007, 61, 67-71.
33. Siegel, M.; Xia, J.; Khosla, C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg. Med. Chem., 2007, 15, 6253-61.
34. Van Deventer, S.J.; Elson, C.O.; Fedorak, R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology, 1997, 113, 383-9.
35. Salvati, V.M.; Mazzarella, G.; Gianfrani, C.; Levings, M.K.; Stefanile, R.; De Giulio, B.; Iaquinto, G.; Giardullo, N.; Auricchio, S.; Roncarolo, M.G.; Troncone, R. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut, 2005, 54, 46-53.
36. Mulder, C.J.; Wahab, P.J.; Meijer, J.W.; Metselaar, E. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur. J. Gastroenterol. Hepatol., 2001, 13, 1183-8.
37. Korzenik, J.R.; Podolsky, D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug. Discov., 2006, 5, 197-209.
38. Peyrin-Biroulet, L.; Desreumaux, P.; Sandborn, W.J.; Colombel, J.F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet, 2008, 372, 67-81.
39. Di Sabatino, A.; Pickard, K.M.; Gordon, J.N.; Salvati, V.; Mazzarella, G.; Beattie, R.M.; Vossenkaemper, A.; Rovedatti, L.; Leakey, N.A.; Croft, N.M.; Troncone, R.; Corazza, G.R.; Stagg, A.J.; Monteleone, G.; MacDonald, T.T. Evidence for the role of interferonalfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology, 2007, 133, 1175-87.
40. Baslund, B.; Tvede, N.; Danneskiold-Samsoe, B.; Larsson, P.; Panayi, G.; Petersen, J.; Petersen, L.J.; Beurskens, F.J.; Schuurman, J.; van de Winkel, J.G.; Parren, P.W.; Gracie, J.A.; Jongbloed, S.; Liew, F.Y.; McInnes, I.B. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum., 2005, 52, 2686-92.
41. Ferrari-Lacraz, S.; Zanelli, E.; Neuberg, M.; Donskoy, E.; Kim, Y.S.; Zheng, X.X.; Hancock, W.W.; Maslinski, W.; Li, X.C.; Strom, T.B.; Moll, T. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol., 2004, 173, 5818-26.
42. Targan, S.R,; Feagan, B.G.; Fedorak, R.N.; Lashner, B.A.; Panaccione, R.; Present, D.H.; Spehlmann, M.E.; Rutgeerts, P.J.; Tulassay, Z.; Volfova, M.; Wolf, D.C.; Hernandez, C.; Bornstein, J.; Sandborn, W.J. International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE. Trial. Gastroenterology, 2007, 132, 1672-83.
43. Rose, J.W.; Foley, J.; Carlson, N. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep., 2008, 8, 419-26.
44. Feagan, B.G.; Greenberg, G.R.; Wild, G.; Fedorak, R.N.; Paré, P.; McDonald, J.W.; Dubé, R.; Cohen, A.; Steinhart, A.H.; Landau, S.; Aguzzi, R.A.; Fox, I.H.; Vandervoort, M.K. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl J Med., 2005, 352, 2499-507.
45. Bekker, P.; Schreiber, S.; Keshav, S. PROTECT-1, prospective randomized oral therapy evaluation of CCX282-B (TRAFICETEN) in Crohn's disease. Gut, 2007, 56 (Suppl), A23.
46. Schulzke, J.D.; Bentzel, C.J.; Schulzke, I.; Riecken, E.O.; Fromm, M. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr. Res., 1998, 43, 435-41.
47. Drago, S.; El Asmar, R.; Di Pierro, M.; Grazia Clemente, M.; Tripathi, A.; Sapone, A.; Tacar, M.; Iacono, G.; Carroccio, A.; D'Agate, C.; Not, T; Zampini, L.; Catáis, C.; Fasano, A. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand. J. Gastroenterol., 2006, 41, 408-19
48. Lammers, K.M.; Lu, R.; Brownley, J.; Lu, B.; Gerard, C.; Thoma, K.; Rallabhandi, P.; Shea-Donohue, T.; Tamiz, A.; Alkan, S.; Netzel-Arnett, S.; Antalis, T.; Vogel, S.N.; Fasano, A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 2008, 135, 194-204.e3.
49. Paterson, B.M.; Lammers, K.M.; Arrieta, M.C.; Fasano, A.; Meddings, J.B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol. Ther., 2007, 26, 757-66.
50. Sanz, Y.; Sánchez, E.; De Palma, G.; Medina, M; Marcos, A.; Nova, E. In Child Nutrition & Physiology, Linda, T.O.; Ewente, M R., Eds.; Nova Science Publishers Inc: New York, 2008.
51. Li, Q.; Zhang, Q.; Wang, M.; Zhao, S.; Ma, J.; Luo, N.; Li, N.; Li, Y.; Xu, G.; Li, J. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin. Immunol., 2008, 126, 67-80.
52. Zeng, J.; Li, Y.Q.; Zuo, X.L.; Zhen, Y.B.; Yang, J.; Liu, C.H. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther., 2008, 28, 994-1002.
53. Seth, A.; Yan, F.; Polk, D.B.; Rao, R.K. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol., 2008, 294, G1060-9.
54. Lindfors, K.; Blomqvist, T.; Juuti-Uusitalo, K.; Stenman, S.; Venäläinen, J.; Mäki, M.; Kaukinen, K. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin. Exp. Immunol., 2008, 152, 552-8.
55. Sanz, Y.; Nadal, I.; Sánchez, E. Probiotics as drugs against human gastrointestinal infections. Recent Patents Anti-Infect. Drug Discov., 2007, 2, 148-56.
56. Medina, M.; Izquierdo, E.; Ennahar, S.; Sanz, Y. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications. Clin. Exp. Immunol., 2007, 150, 531-8.
57. Baba, N.; Samson, S.; Bourdet-Sicard, R.; Rubio, M.; Sarfati, M. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T cells. J. Leukoc. Biol., 2008, 84, 468-76.
58. O'Mahony, C.; Scully, P; O'Mahony, D.; Murphy, S.; O'Brien, F.; Lyons, A.; Sherlock, G.; MacSharry, J.; Kiely, B.; Shanahan, F.; O'Mahony, L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog., 2008, 4, 8:e1000112.
59. Foligne, B.; Zoumpopoulou, G.; Dewulf, J.; Ben Younes, A.; Chareyre, F.; Sirard, J.C.; Pot, B.; Grangette, C. A key role of dendritic cells in probiotic functionality. PLoS ONE, 2007, 2, e313.
60. Guarner, F.; Bourdet-Sicard, R.; Brandtzaeg, P.; Gill, H.S.; McGuirk, P.; van Eden, W.; Versalovic, J.; Weinstock, J.V.; Rook, G.A. Mechanisms of disease: the hygiene hypothesis revisited. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3, 275-284.
61. Steidler, L.; Hans, W.; Schotte, L.; Neirynck, S.; Obermeier, F.; Falk, W.; Fiers, W.; Remaut, E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000, 289, 1352-5.
62. Braat, H.; Rottiers, P.; Hommes, D.W.; Huyghebaert, N.; Remaut, E.; Remon, J.P.; van Deventer, S.J.; Neirynck, S.; Peppelenbosch, M.P.; Steidler, L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol., 2006, 4, 754-9.
63. Medina, M.; De Palma, G.; Ribes-Koninckx, C.; Calabuig, M.; Sanz, Y. Bifidobacterium strains suppress in vitro the proinflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J. Inflamm. (Lond.), 2008, 5, 19.